5 most recent filings and news items mentioning IOVA. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/IOVA/news?limit=20"
Pull IOVA filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayIovance Biotherapeutics Inc. filed a regulatory exhibit outlining a corporate overview and forward-looking statements, which includes risk factors and details regarding commercial product development. Sentiment remains neutral as this is a standard informational filing.
View filing at SEC.gov →Iovance Biotherapeutics posted record second-quarter revenue of ~$99 million and raised gross margins, while updating investors to expect a review of its full-year revenue guidance.
View filing at SEC.gov →10 Health Care Stocks With Whale Alerts In Today’s Session
View filing at SEC.gov →Iovance Biotherapeutics, Inc. filed an 8-K exhibit (99.1) containing a corporate overview. The document includes standard forward-looking statements regarding risks related to commercialization, manufacturing, and future financial results.
View filing at SEC.gov →Iovance Biotherapeutics announced that Australia's TGA approved Amtagvi (lifileucel) for previously treated advanced melanoma, marking the company's third marketing authorization for the therapy. This approval addresses a significant market need in Australia, which has the highes
View filing at SEC.gov →